Healthcare Industry News: hereditary angioedema
News Release - April 4, 2016
Therabron Therapeutics Appoints Eric Richman as an Independent Board MemberROCKVILLE, Md., April 4, 2016 -- (Healthcare Sales & Marketing Network) -- Therabron Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing a new standard in respiratory care, today announced the appointment of Eric I. Richman as an independent director to the Company's board of directors.
"I am delighted to welcome Eric to the Company's board," stated Dr. Thomas F. Miller, President and Chief Executive Officer of Therabron. "Eric is a seasoned biopharmaceutical executive with a proven track record of building companies, particularly in strategic business development and commercialization. We look forward to the valuable insights he will bring to our Company as we advance our novel, potentially first-in-class respiratory disease biologics pipeline."
Mr. Richman has extensive experience in the development and commercialization of novel biotechnology-based therapeutics, most recently as President and Chief Executive Officer of PharmAthene, Inc., a NYSE-listed development-stage company, where he remains on the board of directors. Previously, Mr. Richman was part of the founding team at MedImmune, Inc. where he was responsible for the U.S. launch of MedImmune's first commercial product, CytoGam®, and was an integral part of the global launch teams for marketed products including Synagis®, which generated peak annual sales over $1 billion. He was Chair of the Commercialization Committee as a director of LEV Pharmaceuticals, which launched the first HAE (hereditary angioedema) drug in the United States, until its acquisition by ViroPharma, Inc. Prior to joining MedImmune, he began his career at HealthCare Ventures, a life-sciences focused venture capital firm investing in pre-clinical or early clinical stage companies with potential to transform patient care. Mr. Richman received a B.S. in Biomedical Science from the Sophie Davis School of Biomedical Education (CUNY Medical School) and a Masters of Business Administration from the American Graduate School of International Management. Mr. Richman currently serves on the board of directors of PharmAthene, Inc. and ADMA Biologics, Inc.
About Therabron Therapeutics, Inc.
At Therabron Therapeutics, we are advancing a platform of novel therapeutic proteins in an effort to change how a variety of neglected and under-treated respiratory and fibrotic conditions are managed. We are a privately held, clinical-stage biopharmaceutical company, developing a new class of drugs based on the naturally occurring secretoglobin family of proteins, which includes the CC10 protein — a molecule with both anti-inflammatory and immunomodulatory mechanisms. Therabron's product candidates have the potential to become first-in-class biologic therapeutics. For additional information, please visit www.therabron.com.
Source: Therabron Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.